CRISPR Therapeutics CRSP has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a market capitalization of $3.91 billion.
Buying $100 In CRSP: If an investor had bought $100 of CRSP stock 5 years ago, it would be worth $281.15 today based on a price of $49.91 for CRSP at the time of writing.
CRISPR Therapeutics's Performance Over Last 5 Years
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.